NASDAQ:PHVS Pharvaris (PHVS) Stock Price, News & Analysis → The Next Nvidia? (From InvestorPlace) (Ad) Free PHVS Stock Alerts $20.87 +1.71 (+8.92%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$18.25▼$20.8750-Day Range$18.42▼$27.8152-Week Range$7.93▼$33.00Volume50,600 shsAverage Volume73,019 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$32.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Pharvaris alerts: Email Address Pharvaris MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside55.7% Upside$32.50 Price TargetShort InterestHealthy0.10% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.67Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.20) to ($2.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.46 out of 5 starsMedical Sector539th out of 910 stocksPharmaceutical Preparations Industry242nd out of 423 stocks 3.3 Analyst's Opinion Consensus RatingPharvaris has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoveragePharvaris has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.10% of the float of Pharvaris has been sold short.Short Interest Ratio / Days to CoverPharvaris has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pharvaris has recently decreased by 33.56%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPharvaris does not currently pay a dividend.Dividend GrowthPharvaris does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PHVS. Previous Next 2.6 News and Social Media Coverage News SentimentPharvaris has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Pharvaris this week, compared to 2 articles on an average week. Previous Next N/A Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pharvaris insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Pharvaris are expected to decrease in the coming year, from ($2.20) to ($2.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pharvaris is -7.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pharvaris is -7.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPharvaris has a P/B Ratio of 4.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThe Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.Go here now for this breaking story. About Pharvaris Stock (NASDAQ:PHVS)Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.Read More PHVS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHVS Stock News HeadlinesApril 23, 2024 | americanbankingnews.comPharvaris' (PHVS) "Overweight" Rating Reaffirmed at Morgan StanleyApril 19, 2024 | americanbankingnews.comPharvaris Forecasted to Earn Q4 2024 Earnings of ($0.54) Per Share (NASDAQ:PHVS)April 23, 2024 | InvestorPlace (Ad)The Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.April 16, 2024 | americanbankingnews.comPharvaris (NASDAQ:PHVS) Price Target Cut to $34.00 by Analysts at Morgan StanleyApril 15, 2024 | markets.businessinsider.comPharvaris Earns Buy Rating as Deucrictibant Shows Promising Progress in HAE TreatmentApril 15, 2024 | americanbankingnews.comPharvaris (NASDAQ:PHVS) Forecasted to Earn FY2028 Earnings of $1.43 Per ShareApril 13, 2024 | americanbankingnews.comPharvaris (NASDAQ:PHVS) Rating Reiterated by WedbushApril 13, 2024 | americanbankingnews.comJMP Securities Increases Pharvaris (NASDAQ:PHVS) Price Target to $50.00April 23, 2024 | InvestorPlace (Ad)The Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.April 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pharvaris on Strong HAE Drug Potential and Solid FinancialsApril 12, 2024 | finance.yahoo.comPharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth PlansApril 12, 2024 | investing.comPharvaris appoints new CFO to bolster financial strategyApril 11, 2024 | finanznachrichten.dePharvaris N.V.: Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateApril 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pharvaris on Strong Clinical Progress and Financial StabilityApril 11, 2024 | seekingalpha.comPHVS Pharvaris N.V.April 10, 2024 | investorplace.comPHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023April 10, 2024 | globenewswire.comPharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateApril 10, 2024 | globenewswire.comPharvaris Appoints David Nassif, J.D., as Chief Financial OfficerApril 4, 2024 | globenewswire.comPharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 ConferenceMarch 18, 2024 | globenewswire.comPharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE CongressesMarch 6, 2024 | globenewswire.comPharvaris to Present Deucrictibant Clinical Data at Upcoming CongressesMarch 5, 2024 | globenewswire.comPharvaris to Participate in the Leerink Global Biopharma Conference 2024February 26, 2024 | markets.businessinsider.comPharvaris Buy Rating Affirmed on Strong Phase 2 Data and Market Positioning for HAE TreatmentFebruary 25, 2024 | msn.comPharvaris N.V. (PHVS) Price Target Increased by 6.19% to 34.97February 22, 2024 | finance.yahoo.comPositive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual MeetingFebruary 22, 2024 | globenewswire.comPositive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual MeetingFebruary 16, 2024 | finance.yahoo.comPharvaris Announces Extraordinary Meeting of ShareholdersSee More Headlines Receive PHVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharvaris and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today4/22/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PHVS CUSIPN/A CIK1830487 Webwww.pharvaris.com Phone31-71-203-6410FaxN/AEmployees82Year FoundedN/APrice Target and Rating Average Stock Price Target$32.50 High Stock Price Target$50.00 Low Stock Price Target$11.00 Potential Upside/Downside+55.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-109,180,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-47.92% Return on Assets-44.45% Debt Debt-to-Equity RatioN/A Current Ratio27.25 Quick Ratio27.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.94 per share Price / Book4.22Miscellaneous Outstanding Shares31,840,000Free FloatN/AMarket Cap$664.50 million OptionableNot Optionable Beta-3.12 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Berndt Axel Edvard Modig CPA (Age 65)M.B.A., Co-Founder, CEO & Executive Director Comp: $565.02kMs. Anna Nijdam M.Sc. (Age 43)R.A., Head of Strategic Finance & Principal Accounting Officer Key CompetitorsContext TherapeuticsNASDAQ:CNTXGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPView All CompetitorsInstitutional OwnershipBlackstone Inc.Bought 100,000 shares on 2/15/2024Ownership: 0.314%venBio Partners LLCBought 654,832 shares on 2/14/2024Ownership: 15.451%Commodore Capital LPBought 800,000 shares on 2/14/2024Ownership: 2.513%Bain Capital Life Sciences Investors LLCSold 880,355 shares on 2/13/2024Ownership: 0.000%Vivo Capital LLCBought 285,000 shares on 2/7/2024Ownership: 0.000%View All Institutional Transactions PHVS Stock Analysis - Frequently Asked Questions Should I buy or sell Pharvaris stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pharvaris in the last year. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PHVS shares. View PHVS analyst ratings or view top-rated stocks. What is Pharvaris' stock price target for 2024? 4 Wall Street analysts have issued 12-month target prices for Pharvaris' shares. Their PHVS share price targets range from $11.00 to $50.00. On average, they predict the company's stock price to reach $32.50 in the next year. This suggests a possible upside of 55.7% from the stock's current price. View analysts price targets for PHVS or view top-rated stocks among Wall Street analysts. How have PHVS shares performed in 2024? Pharvaris' stock was trading at $28.05 at the start of the year. Since then, PHVS stock has decreased by 25.6% and is now trading at $20.87. View the best growth stocks for 2024 here. Are investors shorting Pharvaris? Pharvaris saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 9,900 shares, a drop of 33.6% from the March 15th total of 14,900 shares. Based on an average daily volume of 104,100 shares, the short-interest ratio is currently 0.1 days. Currently, 0.1% of the company's shares are sold short. View Pharvaris' Short Interest. When is Pharvaris' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our PHVS earnings forecast. How were Pharvaris' earnings last quarter? Pharvaris (NASDAQ:PHVS) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.39) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.10. When did Pharvaris IPO? Pharvaris (PHVS) raised $126 million in an initial public offering on Friday, February 5th 2021. The company issued 7,000,000 shares at $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink served as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers. How do I buy shares of Pharvaris? Shares of PHVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PHVS) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
